Background: Primary insomnia (PI) is one of the most common complaints among the general population. Both non-pharmacological and pharmacological therapies have proven effective in treating primary insomnia. However, the underlying mechanism of treatment remains unclear, and no studies have compared the underlying mechanisms of different treatments.
Introduction
Primary insomnia (PI) is one of the most prevalent chronic sleep disorders and affects approximately 2-4% of the general population (Ohayon, 2002) . Long-standing primary insomnia can reduce quality of life, hinder work productivity, impair social function, and become life-threatening (Riemann and Voderholzer, 2003; Shekleton et al., 2010) . As a result, insomnia has become the second major cause of patient visits to neurological clinics, after headaches (Wade, 2010) .
Recent brain imaging studies have indicated that insomnia is associated with anatomical and functional alterations in neural systems involved in general arousal, emotion and reward, and prefrontal cognitive control (Khazaie et al., 2017; Spiegelhalder et al., 2015) . Literature suggests that brain regions such as the hippocampus (Joo et al., 2014) , rostral anterior cingulate cortex (rACC) (Winkelman et al., 2013) , orbitofrontal cortex (OFC) (Altena et al., 2010) , dorsolateral prefrontal cortex (DLPFC) (Huang et al., 2017) , and amygdala (Baglioni et al., 2014) are involved in the pathophysiology and development of insomnia.
One of the most well-studied regions in insomnia studies is the hippocampus (Neylan et al., 2010; Riemann, D et al., 2007; Taki et al., 2012) . As a subcortical structure, the hippocampus is crucially involved in learning and memory formation, encoding of spatial information, and emotion regulation (Girardeau et al., 2017; Kreutzmann et al., 2015) .
Animal studies indicate that prolonged stress exposure and sleep loss can suppress hippocampal cell proliferation and neurogenesis (Bhagya et al., 2017; Murata et al., 2017) , which in turn affects local structural and functional integrity, as well as the interaction of the hippocampus (Bhagya et al., 2017) . In previous studies, findings on A C C E P T E D M A N U S C R I P T 4 abnormal hippocampal structure in insomnia are mixed. Some studies have reported a reduced bilateral hippocampus volume in insomnia patients (Joo et al., 2014; Riemann, Dieter et al., 2007) or a negative association between hippocampal atrophy and cognitive impairment (Koo et al., 2017) . In contrast, other studies have found that the hippocampus volumes in individuals with PI did not significantly differ from those of normal sleepers (Noh et al., 2012; Spiegelhalder et al., 2013; Winkelman et al., 2010) .
These contrasting results could be due to differences in anatomical delineation of the hippocampus and differences in insomnia duration (O'Byrne et al., 2014) .
In a recent study, Leerssen et al. (Leerssen et al., 2018) found that relative to healthy controls, patients with insomnia disorder showed a significantly stronger connectivity of the bilateral hippocampus with the left middle frontal gyrus. The individual differences in the strength of this connectivity were associated with insomnia severity and subjective sleep quality. In another recent study (Lee, Y.G. et al., 2018) , investigators found that PI patients exhibited weaker FC between the left hippocampus and left fusiform gyrus compared to controls, and these altered brain responses reversed after five sessions of cognitive-behavioral therapy. Taken together, these studies demonstrate the important role of the hippocampus in the neuropathology of insomnia.
Pharmacological intervention play an important role in the treatment of insomnia (Holbrook et al., 2001; Winkler et al., 2014) . However, it is associated with unwanted side effects (Holbrook et al., 2001) . The cognitive behavioral therapy for insomnia (CBT-I) is the mainstay of non-pharmacologic management of chronic insomnia (Morin, 2006; Trauer et al., 2013) . Problems with accessibility and cost effectiveness mean that many chronic insomniacs do not benefit from this treatment (Kaystacey and Attarian, 2016) .
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Recently, other non-pharmacological methods, such as aerobic physical exercise, music therapy, acupuncture, and cupping (Altena et al., 2008; Kim et al., 2017; Lee, Y.-J.G. et al., 2018; Stoffers et al., 2013; Wilt et al., 2016; Yeung et al., 2012a; Yeung et al., 2012b; Yeung et al., 2011) have drawn the attention of investigators. Cupping therapy, a promising and safe non-pharmacological treatment originating fro m China, is applied by placing cups on selected locations to create suction and produce hyperemia or hemostasis. Some researchers believe that cupping may suppress the proliferation of harmful inflammatory mediators, biological, chemical, or other unwanted substances, and increase the flow of blood to the skin and muscle, stimulating peripheral nerves, neurohormones, and the circulatory and immune systems (El Sayed et al., 2013; Niasari et al., 2007) . In a previous study , we found that cupping can significantly improve the quality of sleep and alleviate anxiety and depression symptoms in insomniacs compared with pharmacologic treatments. The beneficial effect of cupping to relieve the symptoms of insomnia have also been achieved from other studies (Li and Zhang, 2013; Zhang et al., 2010; Zhu et al., 2013) . Nevertheless, the underlying mechanism of cupping remains unknown.
The present study aims to comparatively investigate the treatment effects of benzodiazepines and cupping, as well as their underlying mechanisms, by investigating the brain structural and functional connectivity changes after different treatments in patients with PI. Based on previous findings (Altena et al., 2010; Joo et al., 2014; Neylan et al., 2010; Riemann, D et al., 2007) , we hypothesized that hippocampal volumetric alterations would be reversible upon successful therapy, and that both non- 
Methods

Subjects
Subjects with primary insomnia were recruited. The experiment was approved by the (2) insomnia caused by serious organic disease or severe mental disease secondary to depression (Self-Rating Depression Scale > 70) (Lennard et al., 2011) or generalized anxiety (Self-Rating Anxiety Scale > 70); (3) abnormal findings, such as infarction or focal lesion, on conventional brain MR images; (4) pregnant, nursing, or lactating; and (5) MRI contraindications, such as claustrophobia, metallic implants, or devices in the body. 
Experimental procedure
This study was a pragmatic randomized, open-labeled neuroimaging trial with three arms. After screening, eligible participants were randomized into one of three groups: (i) cupping group; (ii) benzodiazepine group; (iii) wait-list control group (Figure 1) . Patients were instructed to complete a diary booklet each day to describe any side effects they believed to be related to treatment.
Cupping treatment
All cupping was applied by licensed Traditional Chinese Medicine doctors with over 5 years of experience in the clinical practice. Acupoints applied in the cupping group were identical to our previous randomized clinical trial . Details of the cupping technique are shown in Supplementary Table 1 and Figure 2 . The entire treatment totaled 20 minutes. Participants in the cupping group received cupping treatment twice a week for four weeks, totaling up to eight treatment sessions.
Benzodiazepine treatment
Patients in the benzodiazepine group were instructed to take Estazolam tablets (2nd branch of Sinepharm, Shanghai Pharmaceutical. Ltd. Patch No. 060301-01, Strength 1 mg/tablet) daily for four weeks. Estazolam (1 mg) was given 30-60 minutes prior to bedtime every day. A 2 mg dosage of Estazolam was allowed for patients if the Pittsburgh Sleep Quality Index (PSQI) was greater than or equal to 14.
Wait-list control
Patients in the control group did not receive any treatment. After the completion of the full observational period, patients in the control group were provided compensation for transportation, and free cupping treatment was provided if required.
Clinical outcomes and data analysis
All clinical outcomes were measured at week 0 (baseline) and week 4 (posttreatment). The primary measurement was the Pittsburgh Sleep Quality Index (PSQI).
In addition, the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) were applied as secondary clinical outcomes.
Clinical outcome analysis was performed using SPSS 22.0 Software (SPSS Inc., Chicago, IL, USA). One-way ANOVA and Chi-square tests were applied to compare the baseline characteristics of the subjects among groups. An ANCOVA was applied to compare the changes in PSQI, SAS, and SDS scores across the three groups, with age, gender, and duration as covariates. Post-hoc analysis with Bonferroni correction was applied to explore between-group differences. During the MRI, all patients were instructed to relax with their eyes closed without falling asleep.
Imaging acquisition
Brain structure analysis using VBM
VBM was performed using Statistical Parametric Mapping (SPM12) (Wellcome Department of Cognitive Neurology, University College, London, UK) running under a MATLAB suite (MathWorks, Inc., Natick, Massachusetts). First, all images were checked for artifacts, structural abnormalities, and pathologies. Then, the images were segmented into grey matter (GM), white matter, and cerebrospinal fluid (CSF) and normalized using the high dimensional DARTEL algorithm (Ashburner, 2007) .
Subsequently, a group specific template was created to reduce variability between participants. The template was then used to normalize the images into the standard Montreal Neurological Institute (MNI) space using the "DARTEL Normalize to MNI Space" program and the "preserve amount" op tion to retain the volumetric data of the original images. Finally, spatial smoothing was performed with an isotropic Gaussian kernel of 8 mm full-width at half maximum.
Group analysis was applied using a random effects model. We first compared the pretreatment regional grey matter volume (GMV) differences between the three groups using a one-way ANOVA. Then we performed second level analyses using a factorial design module in SPM12 to explore the differences among the three groups. There
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A C C E P T E D M A N U S C R I P T 10 were two factors included in the analysis. The first factor had three levels (cupping group, benzodiazepine group, and control group), and the second factor had two levels (pre-treatment and post-treatment). Age (year), gender, and duration (month) were also included in the model as covariates. Similar to a previous study (Kalmady et al., 2014) , an absolute threshold of 0.1 was used for masking. Total intracranial volume was obtained by summing up the overall volumes of GM, white matter, and CSF.
Given the important role of the hippocampus in neural plasticity changes following insomnia (Joo et al., 2014; Khazaie et al., 2017) , the left and right hippocampus, derived from automated anatomical labeling (AAL) using WFU-Pick Atlas software (Maldjian et al., 2003) , were selected as regions of interest (ROIs). For between-group comparisons, we applied a threshold of p < 0.001 and small volume false discovery rate (FDR) corrected p < 0.05 in the ROI as defined above. A threshold of voxel -wise < 0.001 uncorrected and cluster-level p < 0.05 FDR correction was applied to non-ROI brain regions. Whole-brain second level group analysis was applied using two sample t-tests to compare the hippocampal functional connectivity changes between different groups.
Seed based functional connectivity analysis
Age, gender, and duration were included as covariates of non-interest. A threshold of voxel-wise p < 0.005 uncorrected and cluster-level p < 0.05 FDR corrected was applied in data analysis.
To explore the association between the rsFC changes and PSQI improvement, we also extracted the average z score values of the significantly altered rsFC clusters before and after the treatment (cupping versus control and benzodiazepines versus control), and performed partial correlation analysis using SPSS 22.0 Software to test the association between the significantly altered rsFC clusters and PSQI changes, controlling for age, gender, and duration.
Results
Seventy-three patients with PI were recruited for this study. Of the 67 participants who passed screening and finished baseline scans, 50 (17 in the cupping treatment
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A C C E P T E D M A N U S C R I P T 12 group, 16 in the benzodiazepine treatment group, 17 in the wait-list control group) completed the study. Seventeen patients did not participate in the second fMRI scan due to scheduling conflicts (5 in the cupping group, 7 in the benzodiazepine group, 5 in the control group). A flowchart of this study can be found in Figure 1 . Of the 50 patients who participated in the two fMRI scans, 2 patients were excluded from data analysis due to incomplete scans (lack of resting state fMRI or T1 anatomy; 1 in the benzodiazepine group, 1 in the control group).
Clinical outcomes
Baseline characteristics for the 50 patients who completed the study are detailed in Table 1 . There were no significant differences in age, gender, duration, PSQI score, SAS score, and SDS score among the three groups at baseline (all p > 0.05).
ANCOVA on PSQI score change (post-treatment minus pre-treatment) showed a significant group difference among the three groups (F (2,42) = 73.982, p < 0.001). Posthoc analysis showed that the cupping and benzodiazepine groups produced a significant decrease in PSQI scores compared to the control group (cupping vs control: p Bonferroni < 0.001; Cohen's d = 2.07; benzodiazepines vs control: p Bonferroni < 0.001, Cohen's d = 2.17). There was no significant difference among the two treatment groups in PSQI score change (Cohen's d = 0.32) ( Table 1) . For the control group, there was no significant change from pre-treatment to post-treatment PSQI scores (T = -1.518, p = 0.38).
A C C E P T E D M
A N U S C R I P T 13 ANCOVA on secondary clinical outcomes showed that the two treatment groups both had lower SAS scores than the control group at 4 weeks (Table 1) 
VBM analysis results
To explore the baseline differences in GMV, we first applied a comparison between all groups using a one-way ANOVA. No significant differences were observed among the three groups at baseline.
After 4 weeks of treatment, we observed significant GMV increases in the cupping group compared to the control group at the right hippocampus (cluster size 41, MNI peak coordinates: 38; -29; -14, small-volume corrected at FDR p=0.039). There were no
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14 other significant findings. No significant differences were observed in other betweengroup comparisons (cupping vs. benzodiazepine and benzodiazepine vs. control).
Within group comparison showed no pre-and post-treatment differences across all three groups at the threshold we set. When we applied a relatively less conservative threshold of voxel-wise p < 0.001 uncorrected with 20 continuous voxels, we found that compared to the pre-cupping, the GMV in the right hippocampus, left putamen/insula, and right superior frontal gyrus increased after cupping treatment.
Functional connectivity results
To explore whether there was a significant difference in head movement between the three groups, we extracted six average head movement parameters with CONN software and performed a one-way ANOVA. No significant difference was found in average head movement among the three groups (F = 0.42, p = 0.73).
There was significantly increased connectivity between the right hippocampus and left rostral anterior cingulate cortex/medial prefrontal cortex (rACC/mPFC) in the cupping group compared to controls after longitudinal treatment (Table 2; Figure 3B , shown in red). Benzodiazepine treatment also produced greater rsFC increases between the right hippocampus and left rACC/mPFC compared to the control group (Table 2; Figure 3B, shown in green). In addition, the cupping group showed increased left hippocampus and left rACC/mPFC compared to the control group (Table 2) . There were no right/left hippocampal rsFC differences in any brain region between the cupping and benzodiazepine groups at the threshold we set.
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Within group comparisons showed that there was significantly increased ('post' minus 'pre') rsFC between the right hippocampus and right putamen/insula (cluster size 472; MNI peak coordinates: 30, 2, 2; FDR p=0.015) after treatment in the cupping group.
There were no other significant pre-and post-treatment rsFC differences in all three groups.
To explore the association between rsFC changes and corresponding clinical outcome changes, we investigated the association between right-hippocampus-related rsFC activity and PSQI score changes in the cupping and benzodiazepine groups separately. The partial correlation between PSQI score decreases (clinical improvement) and right hippocampus and rACC/mPFC rsFC changes (scan 2scan 1) was significant in the cupping group (r = −0.65, p = 0.01) (Figure 3A) . Similarly, PSQI score decreases were significantly negatively associated with right hippocampal and rACC/mPFC rsFC change in the benzodiazepine group (r = −0.65, p = 0.01) ( Figure   3C ).
Further exploratory association found no significant association between the SAS and rsFC between the right hippocampus and rACC/mPFC rsFC in both cupping (p = 0.82) and benzodiazepine (p = 0.14) groups. There was also no significant association between the SDS and right hippocampus -rACC/mPFC rsFC in these two treatment groups (cupping, p = 0.99; benzodiazepine, p = 0.63).
Discussion
In the present study, we examined the effects of 4 weeks of pharmacological
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16 treatment (benzodiazepines) and cupping on primary insomnia, as well as their underlying mechanisms. We found that compared to the wait-list control group, both cupping and benzodiazepine treatment groups showed significant clinical remission of insomnia symptoms. VBM analyses revealed significant GMV increases at the right hippocampus after 4 weeks of cupping treatment compared to the control group. Seedbased rsFC analyses showed that both cupping and benzodiazepine treatments significantly increased rsFC between the right hippocampus and left rACC/mPFC compared to the control group. There was a negative association between insom nia symptom reduction and rsFC increases between the right hippocampus and left rACC/mPFC in the two treatment groups, implying that cupping and benzodiazepines may achieve treatment effects by modulating a common network.
Previous studies suggest that cupping can produce significant physiological effects.
For instance, literature suggests that cupping can promote peripheral blood circulation (Ke et al., 2016) , improve local anaerobic metabolism (Emerich et al., 2014) , reduce inflammation (Lin et al., 2014) , and modulate the cellular immune system (Seçilmiş, 2013) . In this study, we found that compared to the no-treatment control group, both cupping and benzodiazepine treatment groups showed a significant decrease in PSQI scores, but, there was no significant difference between the two treatment groups in PSQI score change. Our results are consistent with previous findings indicating that both cupping (Li and Zhang, 2013; Zhang et al., 2010; Zhu et al., 2013) and pharmacologic Hall-Porter et al., 2010; Kuriyama and Tabata, 2017) interventions can significantly relieve the symptoms of insomnia. Therefore, our
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17 study suggests that non-drug treatment options, such as cupping, may be a promising alternative strategy for treating primary insomnia.
We found a significant GMV increase in the right hippocampus after 4 weeks of cupping intervention compared with controls. The observed brain morphometry changes in the hippocampus are in line with neurobiological models of insomnia that assume a dysfunction of brain areas associated with cognitive impairment. Literature suggests that daytime cognitive impairments and deficits in memory consolidation during sleep can be observed in individuals with PI, especially impairment in hippocampusdependent memory consolidation (Mander et al., 2013; Suzanna and J Martin, 2007) .
For example, Riemann et al. (Riemann, D et al., 2007) reported a 15% reduction in bilateral hippocampal volumes in eight patients with primary insomnia in comparison to eight healthy sleepers. Joo et al. (Joo et al., 2014) also reported hippocampal volume loss in 27 patients with primary insomnia compared to 30 healthy sleepers across several hippocampal subfields. Our results suggest that successful nonpharmacological treatment may increase hippocampal volume to modulate the disturbed cognitive process.
The symptoms of insomnia are not limited to sleep and may best be summarized as a round-the-clock state of hyper-arousal, assuming an interplay between psychological and physiological factors in the etiology and perpetuation of primary insomnia (Perlis et al., 1997; Riemann et al., 2010) . The hyper-aroused brain activity was changed in several core brain functional networks, including the default-mode network (DMN, hippocampus, ACC, and mPFC) and salience network (SN, ACC), which are associated with arousal. Specifically, it has been argued that the DMN may play a critical role in
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18 conscious awareness (Horovitz et al., 2009 ). Moreover, it has been shown that sleep deprivation, such as what might occur in insomnia, leads to aberrant stability and function of the DMN (De Havas et al., 2012; Gujar et al., 2014) . The SN, the central network for detecting and filtering salient stimuli (Peters et al., 2016) , has been demonstrated to play an important role in hyper-arousal and affective symptoms in patients with insomnia (Chen, Michael C et al., 2014; Huang et al., 2012; Joo et al., 2013 ).
In the present study, we found that both non-pharmacological and pharmacological interventions significantly increased rsFC between the right hippocampus and left rACC/mPFC compared to the control group. We also found a negative association between insomnia symptom improvement and rsFC i ncrease between the right hippocampus and left rACC/mPFC in both cupping and benzodiazepine groups. The ACC is a main node of the salience network (SN) and default mode network (DMN) and plays a critical role in the detection and screening of emotional stimuli (Uddin, 2015) .
Alterations in ACC volume (Winkelman et al., 2013) and abnormal ACC activity (Li, Yongli et al., 2014; have been reported in PI in a previous study.
Literature suggests that the ACC also plays an important role in mediating dynamic interactions between large-scale brain networks involved in internal-oriented tasks (i.e. default mode network) and external-oriented tasks (i.e. central executive network, CEN) (Menon and Uddin, 2010) . Li et al. demonstrated that insomnia patients exhibit increased connectivity between the superior parietal lobule and the right ACC, which are brain regions critical for spatial and verbal working memory (Li, Y. et al., 2014) .
Furthermore, affective and emotional symptoms appear to be closely connected with
aberrations of the SN in patients with insomnia (Chen, M. C. et al., 2014) .
The mPFC is involved in memory, learning, and visuospatial tasks (Wen et al., 1999) and plays an active role in the generation of arousal and insomnia (Demontis et al., 1990) . Previous studies have suggested that the insula and left mPFC are critical regions in maintaining sleep (Chuah et al., 2006; Koenigs et al., 2010) . Moreover, another study reported that individuals with insomnia exhibited decreased activations in the DMN when performing working memory tasks (Drummond et al., 2013) , and there appears to be a strong correlation between changes in the DMN circuitry and severity of insomnia (Regen et al., 2016) . Similarly, changes in connectivity between the anterior DMN and SN may constitute an increase in top-down modulation of limbic hyperactivity, bottom-up interference of self-processing regions, or both, as has been previously argued to occur in depression (Mulders et al., 2015) . As a result, some investigators have posited that insomnia is a network-based disorder (DMN & SN) (Chen, M. C. et al., 2014) . Taken together, our results suggest that both cupping and benzodiazepines may achieve treatment effects by modulating DMN and SN.
We did not find significant functional connectivity differences between the benzodiazepine and control groups using the left hippocampus as a seed at the threshold we set. As an exploratory analysis, we applied a relatively less conservative threshold of voxel-wise p < 0.05 with 100 continuous voxels and found greater connectivity between the left hippocampus and bilateral ACC/mPFC. More studies with larger sample sizes are needed to validate our finding.
There are several limitations to this study. First, the treatment only lasted four weeks.
Thus, the results obtained only represent short-term to mid-term effects. Further study is
needed to evaluate the long-term effects of non-pharmacological and pharmacological interventions. Second, the dropout rate in each group was relatively high; however, we would like to emphasize that the reasons for dropout did not seem to be associated wi th treatment response. Third, we only recruited patients with PI for the benzodiazepine and cupping treatments, so there were no healthy controls (HCs) in this study. This prevents us from exploring modulation effects of different interventions on the disrupted changes in brain structure and function of PI patients as compared to HCs. Fourth, we did not systemically collect the side effects that occurred during cupping or benzodiazepine treatment. Further research is needed to record any side effects corresponding with or temporally related to treatment in a diary booklet. Finally, the sample size is relatively small, and studies with larger sample sizes are needed to further validate our findings.
Conclusion
We found that both cupping and benzodiazepines can significantly modulate hippocampal and rACC/mPFC rsFC. The strengthened functional connection was significantly associated with the therapeutic effects of treatment. Our findings demonstrate the potential of cupping in the treatment of insomnia.
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29 Supplementary Table 1 . Course of cupping technique.
1 Bilateral Gansu (CV4) and Qimen (LR14) were selected as the key acupoints receiving cupping stimulation 2
Participants were asked to sit comfortably in a chair with both feet flat on the floor and expose their back regions 3
Mark acupoints for cupping with a surgical marker 4
Disinfect the acupoints with alcohol 5
Puncture the acupoints with a needle, then attach glass cups on the skin 6
Ignite an alcohol swab, and then the burning swab is quickly placed inside the cup and withdrawn 7
Remove cups after 10 min 8
Swab and stanch the treated sites with a dry cotton ball
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